Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

BACKGROUND: Lenvatinib has been approved in Italy since October 2019 as a first-line therapy for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness and safety of lenvatinib are not available in our region. To fill this gap, we performed a multicentric analysis of the real-worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgio, Valentina, Iavarone, Massimo, Di Costanzo, Giovanni Giuseppe, Marra, Fabio, Lonardi, Sara, Tamburini, Emiliano, Piscaglia, Fabio, Masi, Gianluca, Celsa, Ciro, Foschi, Francesco Giuseppe, Silletta, Marianna, Amoruso, Daniela Caterina, Rimini, Margherita, Bruccoleri, Mariangela, Tortora, Raffaella, Campani, Claudia, Soldà, Caterina, Viola, Massimo Giuseppe, Forgione, Antonella, Conti, Fabio, Salani, Francesca, Catanese, Silvia, Giacchetto, Carmelo Marco, Fulgenzi, Claudia, Coppola, Carmine, Lampertico, Pietro, Pellino, Antonio, Rancatore, Gabriele, Cabibbo, Giuseppe, Ratti, Francesca, Pedica, Federica, Della Corte, Angelo, Colombo, Massimo, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, Casadei-Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713715/
https://www.ncbi.nlm.nih.gov/pubmed/34992463
http://dx.doi.org/10.2147/CMAR.S330195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713715/
https://www.ncbi.nlm.nih.gov/pubmed/34992463
http://dx.doi.org/10.2147/CMAR.S330195

Ejemplares similares